Pharmaceutical innovators and generic companies use Physiologically Based Biopharmaceutics Models (PBBMs) to guide drug product development and potentially waive clinical pharmacokinetic studies for both pre- and postapproval changes. This modeling approach can assist with biopharmaceutics risk assessment and the establishment of patient centric, clinically relevant drug product specifications. However, the variability of possible model strategies and the existence of gaps in scientific knowledge associated with the lack of standardized regulatory expectations for model parametrization, data requirements for model development, and criteria for fit-for-purpose model validation leads to varied acceptance rates and frequent requests for additional information and deficiencies in PBBM submissions across regulatory agencies. During the 2023 Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) PBBM Best Practices for Drug Product Quality: Regulatory and Industry Perspectives workshop, it was identified that a PBBM report template summarizing model considerations and proposing a structure for presenting question(s) of interest, model context, input data, a modeling plan, and validation would be beneficial for both industry and regulatory agencies. The present work is not a regulatory guideline but rather a summary of current best practices and considerations for PBBM submissions. The associated template can be downloaded directly from the Supporting Information to guide one in the preparation of PBBM reports. The current paper discusses the critical elements of the PBBM report template, which were identified during the industry-regulator scientific collaboration and interactions.
7 September 2021 in Reaction Chemistry & Engineering
The value of reaction kinetic models for manufacturing APIs (active pharmaceutical ingredients) has been well established in the quality by design (QbD) paradigm. Creating such models during the early phase of development when data and material are scarce is challenging. In this work, we present a model-based design of experiments framework for selecting a “fit for purpose” kinetic model from limited data. The framework leverages an estimability analysis to facilitate parameterizing candidate models. The essential elements can be applied in other domains where model selection is required, but an illustrative case study is presented for selecting the best of three proposed kinetic models for the 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)-catalyzed N-methylation of a key intermediate in an API process using dimethyl carbonate (DMC). The case study concludes by selecting a mechanism that invokes an N-methylated DBU species as a key intermediate over other plausible mechanisms previously suggested in the literature. The framework is conceptually straightforward and requires minimal coding and computational time to execute.
17 January 2024 in The Journal of Physical Chemistry B